MiR-145 Functions As a Tumor Suppressor Via Regulating Angiopoietin-2 in Pancreatic Cancer Cells

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2016 Aug 30

PMID 27570490

Citations 20

Authors

Hao Wang

Cheng Hang

Xi-Long Ou

Jin-Shan Nie

Yi-Tao Ding

Shi-Gui Xue

Hua Gao

Jian-Xin Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer is currently one of the leading causes of cancer deaths without any effective therapies. Mir-145 has been found to be tumor-suppressive in various types of cancers. The aim of this study is to investigate the role of miR-145 in pancreatic cancer cells and explore its underlying mechanism.

Methods: Quantitative real time PCR was used to determine the expression level of miR-145 and angiopoietin-2 (Ang-2) mNRA, and the expression level of Ang-2 protein was measured by western blotting. The anti-cancer activities of miR-145 were tested both in in vitro by using cell invasion and colony formation assay and in vivo by using xenograft assay. The direct action of miR-145 on Ang-2 was predicted by TargetScan and confirmed by luciferase report assay. The vascularization of xenografts were performed by immunohistochemical analysis.

Results: The expression level of miR-145 was significantly lower and the expression levels of Ang-2 mRNA and protein was significantly higher in the more aggressive pancreatic cancer cells (MiaPaCa-2 and Panc-1) when compared to that in BxPC3 cells. Overexpression of miR-145 in the BxPC3, MiaPaCa-2 and Panc-1 cells suppressed the cell invasion and colony formation ability, and the expression level of Ang-2 protein in MiaPaCa-2 and Panc-1 cells was also suppressed after pre-miR-145 transfection. Intratumoral delivery of miR-145 inhibited the growth of pancreatic cancer xenografts and angiogenesis in vivo, and also suppressed the expression level of angiopoietin-2 protein. Luciferase report assay showed that Ang-2 is a direct target of miR-145, and down-regulation of angiopoietin-2 by treatment with Ang-2 siRNA in the BxPC3, MiaPaCa-2 and Panc-1 cells suppressed cell invasion and colony formation ability. The reverse transcription PCR results also showed that Tie1 and Tie2 were expressed in BxPC3, MiaPaCa-2 and Panc-1 cells.

Conclusion: MiR-145 functions as a tumor suppressor in pancreatic cancer cells by targeting Ang-2 for translation repression and thus suppresses pancreatic cancer cell invasion and growth, which suggests that restoring of miR-145 may be a potential therapeutic target for pancreatic cancer.

Citing Articles

Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer.

Yu S, Wang M, Zhang H, Guo X, Qin R J Cell Mol Med. 2024; 28(12):e18444.

PMID: 38924205 PMC: 11196374. DOI: 10.1111/jcmm.18444.

Functional and Potential Therapeutic Implication of MicroRNAs in Pancreatic Cancer.

Pal A, Ojha A, Ju J Int J Mol Sci. 2023; 24(24).

PMID: 38139352 PMC: 10744132. DOI: 10.3390/ijms242417523.

The possible dual role of Ang-2 in the prognosis of pancreatic cancer.

Roos-Mattila M, Kaprio T, Mustonen H, Hagstrom J, Saharinen P, Haglund C Sci Rep. 2023; 13(1):18725.

PMID: 37907568 PMC: 10618172. DOI: 10.1038/s41598-023-45194-0.

Functional Relevance of the Long Intergenic Non-Coding RNA Regulator of Reprogramming (Linc-ROR) in Cancer Proliferation, Metastasis, and Drug Resistance.

Pena-Flores J, Enriquez-Espinoza D, Muela-Campos D, Alvarez-Ramirez A, Saenz A, Barraza-Gomez A Noncoding RNA. 2023; 9(1).

PMID: 36827545 PMC: 9965135. DOI: 10.3390/ncrna9010012.

Ang2-Targeted Combination Therapy for Cancer Treatment.

Liu N, Liu M, Fu S, Wang J, Tang H, Isah A Front Immunol. 2022; 13:949553.

PMID: 35874764 PMC: 9305611. DOI: 10.3389/fimmu.2022.949553.

References

Koh Y, Kim H, Hwang S, Lee J, Oh N, Jung K . Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell. 2010; 18(2):171-84. DOI: 10.1016/j.ccr.2010.07.001. View

He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

Holopainen T, Saharinen P, DAmico G, Lampinen A, Eklund L, Sormunen R . Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst. 2012; 104(6):461-75. PMC: 3309130. DOI: 10.1093/jnci/djs009. View

Lewis C, de Palma M, Naldini L . Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res. 2007; 67(18):8429-32. DOI: 10.1158/0008-5472.CAN-07-1684. View

Khan S, Ebeling M, Zaman M, Sikander M, Yallapu M, Chauhan N . MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget. 2014; 5(17):7599-609. PMC: 4202147. DOI: 10.18632/oncotarget.2281. View

Gregersen L, Jacobsen A, Frankel L, Wen J, Krogh A, Lund A . MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010; 5(1):e8836. PMC: 2809101. DOI: 10.1371/journal.pone.0008836. View

Kavanagh T, Stevens B, Seers K, Sidani S, Watt-Watson J . Process evaluation of appreciative inquiry to translate pain management evidence into pediatric nursing practice. Implement Sci. 2010; 5:90. PMC: 3000375. DOI: 10.1186/1748-5908-5-90. View

Hakanpaa L, Sipila T, Leppanen V, Gautam P, Nurmi H, Jacquemet G . Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nat Commun. 2015; 6:5962. PMC: 4316742. DOI: 10.1038/ncomms6962. View

Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel S . Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell. 2014; 26(6):880-895. DOI: 10.1016/j.ccell.2014.11.005. View

10.

Thurston G, Daly C . The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb Perspect Med. 2012; 2(9):a006550. PMC: 3426817. DOI: 10.1101/cshperspect.a006650. View

11.

Janssen H, Reesink H, Lawitz E, Zeuzem S, Rodriguez-Torres M, Patel K . Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368(18):1685-94. DOI: 10.1056/NEJMoa1209026. View

12.

Xu Q, Liu L, Qian X, Chen Q, Jiang Y, Li D . MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2011; 40(2):761-74. PMC: 3258133. DOI: 10.1093/nar/gkr730. View

13.

Hezel A, Kimmelman A, Stanger B, Bardeesy N, DePinho R . Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006; 20(10):1218-49. DOI: 10.1101/gad.1415606. View

14.

Bouchie A . First microRNA mimic enters clinic. Nat Biotechnol. 2013; 31(7):577. DOI: 10.1038/nbt0713-577. View

15.

Gumireddy K, Young D, Xiong X, Hogenesch J, Huang Q, Deiters A . Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl. 2008; 47(39):7482-4. PMC: 3428715. DOI: 10.1002/anie.200801555. View

16.

Fan L, Wu Q, Xing X, Wei Y, Shao Z . MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai). 2012; 44(5):407-14. DOI: 10.1093/abbs/gms019. View

17.

Sachdeva M, Mo Y . MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2009; 70(1):378-87. PMC: 2805032. DOI: 10.1158/0008-5472.CAN-09-2021. View

18.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

19.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

20.

Boufraqech M, Zhang L, Jain M, Patel D, Ellis R, Xiong Y . miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014; 21(4):517-31. PMC: 8375571. DOI: 10.1530/ERC-14-0077. View